Developmental Therapeutics Program at the NCI: molecular target and drug discovery process

@article{Monga2002DevelopmentalTP,
  title={Developmental Therapeutics Program at the NCI: molecular target and drug discovery process},
  author={M Monga and EA Sausville},
  journal={Leukemia},
  year={2002},
  volume={16},
  pages={520-526}
}
As the drug discovery and developmental arm of the National Cancer Institute (NCI), the Developmental Therapeutics Program (DTP) plans, conducts and facilitates development of therapeutic agents for cancer and AIDS. DTP's goal is to turn ‘molecules into medicine for the public health’. Areas of support by DTP are discovery, development and pathways to development for the intramural and the extramural community. The Developmental Therapeutics Program (DTP) operates a repository of synthetic and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Phase I trial of 7hydroxystaurosporine ( UCN01 ) and fludarabine phosphate ; in vivo evidence of UCN01 induced apoptosis in CLL

  • WH Wilson, M Gutierrez, +7 authors U Hegde
  • ASH Proc
  • 2000

A phase I study of FR 901228 ( Depsipeptide ) , a histone deacetylase inhibitor

  • SE Bates, V Sandor, S Bakke
  • ASCO Proc
  • 1999

Similar Papers

Loading similar papers…